Miscellaneous ePI Test, published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cander2/epi-test/ and changes regularly. See the Directory of published versions
Rapamune
Sirolimus
0.5 mg coated tablets
1 mg coated tablets
2 mg coated tablets
Reference Market: European Union
PACKAGE LEAFLET
Package leaflet: Information for the user
Rapamune 0.5 mg coated tablets
Rapamune 1 mg coated tablets
Rapamune 2 mg coated tablets
Sirolimus
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants. It helps to control your body’s immune system after you have received a kidney transplant.
Rapamune is used in adults to prevent your body from rejecting transplanted kidneys and is normally used with other immunosuppressant medicines called corticosteroids and initially (the first 2 to 3 months) with ciclosporin.
Do not take Rapamune
Warnings and precautions
Talk to your doctor or pharmacist before taking Rapamune
Your doctor will perform tests to monitor the levels of Rapamune in your blood. Your doctor will also perform tests to monitor your kidney function, your blood fat (cholesterol and/or triglycerides) levels and possibly your liver function, during treatment with Rapamune.
Exposure to sunlight and UV light should be limited by covering your skin with clothing and using a sunscreen with a high protection factor because of the increased risk for skin cancer.
Children and adolescents
There is limited experience on the use of Rapamune in children and adolescents less than 18 years of age. The use of Rapamune is not recommended in this population.
Other medicines and Rapamune
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines can interfere with the action of Rapamune and, therefore, dose adjustment of Rapamune may be required. In particular, you should inform your doctor or pharmacist if you are taking any of the following:
The use of live vaccines should be avoided with the use of Rapamune. Before vaccinations, please inform your doctor or pharmacist that you are receiving Rapamune.
The use of Rapamune may lead to increased levels of cholesterol and triglycerides (blood fats) in your blood that may require treatment. Medicines known as “statins” and “fibrates” used to treat elevated cholesterol and triglycerides have been associated with an increased risk of muscle breakdown (rhabdomyolysis). Please inform your doctor if you are taking medicines to lower your blood fats.
The combined use of Rapamune with angiotensin converting enzyme (ACE) inhibitors (a type of medicine used to lower blood pressure) may result in allergic reactions. Please inform your doctor if you are taking any of these medicines.
Rapamune with food and drink
Rapamune should be taken consistently, either with or without food. If you prefer to take Rapamune with food, then you should always take it with food. If you prefer to take Rapamune without food, then you should always take it without food. Food can affect the amount of medicine that gets into your bloodstream and taking your medicine in a consistent way means that the blood levels of Rapamune remain more stable.
Rapamune should not be taken with grapefruit juice.
Pregnancy, breast-feeding and fertility
Rapamune should not be used during pregnancy unless clearly necessary. You must use an effective method of contraception during treatment with Rapamune and for 12 weeks after treatment has stopped. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known whether Rapamune passes into breast milk. Patients taking Rapamune should discontinue breast feeding.
Decreased sperm count has been associated with the use of Rapamune and usually returns to normal once treatment is stopped.
Driving and using machines
Although Rapamune treatment is not expected to affect your ability to drive, if you have any concerns please consult your doctor.
Rapamune contains lactose and sucrose
Rapamune contains 86.4 mg of lactose and up to 215.8 mg of sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will decide exactly what dose of Rapamune you must take and how often to take it. Follow your doctor’s instructions exactly, and never change the dose yourself.
Rapamune is for oral use only. Do not crush, chew, or split the tablets. Inform your doctor if you have difficulty taking the tablet.
Multiples of 0.5 mg tablets should not be used as a substitute for 1 mg and 2 mg tablets, as the different strengths are not directly interchangeable.
Rapamune should be taken consistently, either with or without food.
Kidney Transplant
Your doctor will give you an initial dose of 6 mg as soon as possible after the kidney transplant operation. Then you will need to take 2 mg of Rapamune each day, until otherwise directed by your doctor. Your dose will be adjusted depending on the level of Rapamune in your blood. Your doctor will need to perform blood tests to measure Rapamune concentrations.
If you are also taking ciclosporin, then you must take the two medicines approximately 4 hours apart.
It is recommended that Rapamune be used first in combination with ciclosporin and corticosteroids. After 3 months, your doctor may discontinue either Rapamune or ciclosporin, as it is not recommended that these medicines be taken together beyond this period.
If you take more Rapamune than you should
If you have taken more medicine than you were told to, contact a doctor or go to the nearest hospital emergency department as soon as possible. Always take the labelled blister with you, even if it is empty.
If you forget to take Rapamune
If you forget to take Rapamune, take it as soon as you remember, but not within 4 hours of the next dose of ciclosporin. After that, continue to take your medicines as usual. Do not take a double dose to make up for a forgotten dose, and always take Rapamune and ciclosporin approximately 4 hours apart. If you miss a dose of Rapamune completely, you should inform your doctor.
If you stop taking Rapamune
Do not stop taking Rapamune unless your doctor tells you to, as you risk losing your transplant.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
You should see your doctor immediately if you experience symptoms, such as swollen face, tongue and/or back of the mouth (pharynx) and/or difficulties in breathing (angioedema), or a skin condition whereby the skin can peel off (exfoliative dermatitis). These may be symptoms of a serious allergic reaction.
Kidney damage with low blood cell counts (thrombocytopaenic purpura/haemolytic uraemic syndrome)
When taken with medicines called calcineurin inhibitors (ciclosporin or tacrolimus), Rapamune may increase the risk of kidney damage with low blood platelets and low red blood cell counts, with or without rash (thrombocytopaenic purpura/haemolytic uraemic syndrome). If you experience symptoms such as bruising or rash, changes in your urine, or changes in behaviour or any others that are serious, unusual or prolonged, contact your doctor.
Infections
Rapamune reduces your body’s own defence mechanisms. Consequently, your body will not be as good as normal at fighting infections. So, if you are taking Rapamune, you may therefore catch more infections than usual, such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract (see list below). You should contact your doctor if you experience symptoms that are serious, unusual, or prolonged.
Side effect frequencies
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Not known: frequency cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.
Keep Rapamune out of the sight and reach of children.
Do not use this medicine after the expiry date, which is stated on the blister and carton after “EXP”. The expiry date refers to the last day of that month.
Store below 30ºC.
Keep the blister in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Rapamune contains
The active substance is sirolimus.
Each Rapamune 0.5 mg coated tablet contains 0.5 mg of sirolimus.
Each Rapamune 1 mg coated tablet contains 1 mg of sirolimus.
Each Rapamune 2 mg coated tablet contains 2 mg of sirolimus.
The other ingredients are:
Tablet core: lactose monohydrate, macrogol, magnesium stearate, talc
Tablet coating: macrogol, glycerol monooleate, pharmaceutical glaze, calcium sulfate, microcrystalline cellulose, sucrose, titanium dioxide, poloxamer 188, tocopherol, povidone, carnauba wax, Printing ink (Shellac, Iron Oxide Red, Propylene Glycol, Ammonium Hydroxide, Simethicone). The 0.5 mg and 2 mg tablets also contain yellow iron oxide (E172) and brown iron oxide (E172).
What Rapamune looks like and contents of the pack
Rapamune 0.5 mg is supplied to you as tan coloured, triangular shaped, coated tablets marked “RAPAMUNE 0.5 mg” on one side.
White, triangular-shaped sugar-coated tablet, Rapamune 1 mg, in red ink.
Rapamune 2 mg is supplied to you as yellow to beige coloured, triangular shaped, coated tablets marked “RAPAMUNE 2 mg” on one side.
The tablets are supplied in blister packs of 30 and 100 tablets.
Not all pack sizes or strengths may be marketed.
Marketing Authorisation Holder:
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufactured:
Pfizer Ireland Pharmaceuticals
Little Connell, Newbridge
Co. Kildare
Ireland
Primary Packager, Secondary Packager & Batch Releaser:
Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany
This leaflet was last revised in November 2021.
THIS IS A MEDICAMENT
Keep all medicaments out of reach and sight of children Council of Arab Health Ministers Union of Arabic Pharmacists |
status: active
Domain: Human use
Combined pharmaceutical dose form:
Legal Status of Supply: Medicinal product subject to medical prescription
Clinical Information